Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers

Clinical Reviews in Allergy and Immunology

Volumn 48, Issue 2-3, 2015, Pages 254-262

  Floreani, Annarosa ^a   Spinazzè, Alice ^a   Caballeria, Llorenc ^b   Reig, Ana ^b   Cazzagon, Nora ^a   Franceschet, Irene ^a   Buja, Alessandra ^a   Furlan, Patrizia ^a   Harada, Kenichi ^c   Leung, Patrick SC ^d   Gershwin, M Eric ^d   Pares, Albert ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Extrahepatic malignancies; PBC; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; MITOCHONDRION ANTIBODY;

ADULT; ADVANCED CANCER; ALCOHOL CONSUMPTION; ARTICLE; AUTOIMMUNITY; BILE DUCT CARCINOMA; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE STUDY; ECHOGRAPHY; ENDOMETRIUM CANCER; EXTRAHEPATIC MALIGNANCY; FAMILY HISTORY; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; ITALY; KIDNEY CANCER; LIVER BIOPSY; LIVER TRANSPLANTATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIDDLE AGED; OVARY CANCER; PANCREAS CANCER; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PROTHROMBIN TIME; SARCOMA; SKIN CANCER; SPAIN; STOMACH ADENOCARCINOMA; SURVIVAL RATE; THROMBOCYTE COUNT; THYROID CANCER; TOBACCO CONSUMPTION; UTERINE CERVIX CANCER; AGED; COMPLICATION; FOLLOW UP; KAPLAN MEIER METHOD; LIVER CIRRHOSIS, BILIARY; NEOPLASMS; REGISTER; RISK FACTOR;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; REGISTRIES; RISK FACTORS; SPAIN;

EID: 84928156700     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-014-8446-7     Document Type: Article

References (68)

1. Bernatsky S, Ramsey-Goldman R, Clarke A (2006) Malignancy and autoimmunity. Curr Opin Rheumatol 18:129–134
2. Szekanecz E, Andras C, Sandor Z, Antal-Szalmas P, Szanto J, Tamasi L, Kiss E et al (2006) Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 6:42–47
3. Ngu JH, Gearry RB, Frampton CM, Stedman CA (2012) Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 55:522–529
4. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C (2011) Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 56:578–585
5. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, Bergquist A et al (2009) Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 50:388–393
6. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36:321–327
7. Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, Shaw SY et al (2014) Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis
8. Nguyen DL, Juran BD, Lazaridis KN (2010) Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol 24:647–654
9. Hirschfield GM, Invernizzi P (2011) Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 31:147–156
10. Liu X, Invernizzi P, Lu Y, Kosoy R, Bianchi I, Podda M, Xu C et al (2010) Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 42:658–660
11. Jones DE (2008) Pathogenesis of primary biliary cirrhosis. Clin Liver Dis 12:305–321, vii
12. Cavazza A, Caballeria L, Floreani A, Farinati F, Bruguera M, Caroli D, Pares A (2009) Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 50:1162–1168
13. Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, Ichida T et al (2013) Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology 57:1942–1949
14. Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF (1997) Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26:1138–1142
15. Floreani A, Farinati F (2013) Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. Hepatology 58:1520–1521
16. Liang Y, Yang Z, Zhong R (2012) Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 56:1409–1417
17. Goudie BM, Burt AD, Boyle P, Macfarlane G, Birnie GG, Mills PR, Gillis CR et al (1985) Breast cancer in women with primary biliary cirrhosis. Br Med J (Clin Res Ed) 291:1597–1598
18. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R et al (1990) The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 12:98–105
19. Wolke AM, Schaffner F, Kapelman B, Sacks HS (1984) Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med 76:1075–1078
20. Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ (2008) Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 20:5–9
21. Floreani A, Baragiotta A, Baldo V, Menegon T, Farinati F, Naccarato R (1999) Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology 29:1425–1428
22. Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF (1999) Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 45:756–760
23. Piscaglia F, Sagrini E (2008) Malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 20:1–4
24. Mells GF, Kaser A, Karlsen TH (2013) Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun 46:41–54
25. Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA (2013) Role of the intestinal microbiome in liver disease. J Autoimmun 46:66–73
26. Liu Y, Li H, Xiao T, Lu Q (2013) Epigenetics in immune-mediated pulmonary diseases. Clin Rev Allergy Immunol 45:314–330
27. Saito Y, Saito H, Liang G, Friedman JM (2013) Epigenetic alterations and microrna misexpression in cancer and autoimmune diseases: a critical review. Clin Rev Allergy Immunol
28. Wichner K, Fischer A, Winter S, Tetzlaff S, Heimesaat MM, Bereswill S, Rehm A et al (2013) Transition from an autoimmune-prone state to fatal autoimmune disease in CCR7 and RORgammat double-deficient mice is dependent on gut microbiota. J Autoimmun 47:58–72
29. Ludwig J (2000) The pathology of primary biliary cirrhosis and autoimmune cholangitis. Bailliere Best Pract Res Clin Gastroenterol 14:601–613
30. Scheuer P (1967) Primary biliary cirrhosis. Proc R Soc Med 60:1257–1260
31. Panjala C, Talwalkar JA, Lindor KD (2007) Risk of lymphoma in primary biliary cirrhosis. Clin Gastroenterol Hepatol 5:761–764
32. Chakravarty E, Genovese MC (2003) Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 15:35–43
33. Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J, Zhang FC et al (2010) Incidence of malignancy in primary Sjogren’s syndrome in a Chinese cohort. Rheumatology (Oxford) 49:571–577
34. Schopper D, de Wolf C (2009) How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer 45:1916–1923
35. Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Allemani C, Gatta G et al (2009) The cure of cancer: a European perspective. Eur J Cancer 45:1067–1079
36. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124:889–893
37. Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, Poupon RE et al (2003) Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 38:203–209
38. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME et al (2011) High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 106:1638–1645
39. Lindstrom L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzen H et al (2012) High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 35:451–457
40. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433–441
41. Goldblatt F, O’Neill SG (2013) Clinical aspects of autoimmune rheumatic diseases. Lancet 382:797–808
42. Invernizzi P (2013) Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. J Autoimmun 46:1–6
43. Hudspeth K, Pontarini E, Tentorio P, Cimino M, Donadon M, Torzilli G, Lugli E et al (2013) The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun 46:55–65
44. Ekstrom Smedly K, Vajdic CM, Palster M et al (2008) Autoimmune disorders and risk in non-Hodgkin lymphoma subtypes: a pooled analysis within the Interlymph Consortium. Blood III:4029–4038
45. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, Cournoyer D et al (2005) Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507–1509
46. Zhang W, Tsuda M, Yang GX, Tsuneyama K, He XS, Ansari AA, Ridgway WM et al (2012) Lymphoma-like T cell infiltration in liver is associated with increased copy number of dominant negative form of TGFbeta receptor II. PLoS One 7:e49413
47. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, Ridgway WM et al (2006) Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 177:1655–1660
48. Wang J, Yang GX, Tsuneyama K, Gershwin ME, Ridgway WM, Leung PS (2014) Animal models of primary biliary cirrhosis. Semin Liver Dis 34:285–296
49. Leung PS, Yang GX, Dhirapong A, Tsuneyama K, Ridgway WM, Gershwin ME (2012) Animal models of primary biliary cirrhosis: materials and methods. Methods Mol Biol 900:291–316
50. Yang CY, Leung PS, Yang GX, Kenny TP, Zhang W, Coppel R, Norman GL et al (2012) Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent. Clin Exp Immunol 168:261–267
51. Ando Y, Yang GX, Tsuda M, Kawata K, Zhang W, Nakajima T, Tsuneyama K et al (2012) The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology 56:1418–1426
52. Tsuda M, Zhang W, Yang GX, Tsuneyama K, Ando Y, Kawata K, Park O et al (2013) Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type II mice. Hepatology 57:806–816
53. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, Moritoki Y, Ansari AA et al (2009) Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 50:1494–1500
54. Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, Ueno Y et al (2009) B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology 50:1893–1903
55. Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, Wakabayashi K, Ansari AA et al (2008) Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 47:1974–1982
56. Tanaka H, Zhang W, Yang GX, Ando Y, Tomiyama T, Tsuneyama K, Leung P et al (2014) Successful immunotherapy of autoimmune cholangitis by adoptive transfer of Foxp3 regulatory T cells. Clin Exp Immunol
57. Kawata K, Yang GX, Ando Y, Tanaka H, Zhang W, Kobayashi Y, Tsuneyama K et al (2013) Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFbetaRII mice. Hepatology 58:1094–1104
58. Podda M, Selmi C, Lleo A, Moroni L, Invernizzi P (2013) The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. J Autoimmun 46:81–87
59. Imam MH, Talwalkar JA, Lindor KD (2013) Clinical management of autoimmune biliary diseases. J Autoimmun 46:88–96
60. Myszor M, James OF (1990) The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med 75:377–385
61. Danielsson A, Boqvist L, Uddenfeldt P (1990) Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 11:458–464
62. Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, Yawn BP et al (2000) Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119:1631–1636
63. Sood S, Gow PJ, Christie JM, Angus PW (2004) Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 127:470–475
64. Pla X, Vergara M, Gil M, Dalmau B, Cistero B, Bella RM, Real J (2007) Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol 19:859–864
65. Wong RK, Lim SG, Wee A, Chan YH, Aung MO, Wai CT (2008) Primary biliary cirrhosis in Singapore: evaluation of demography, prognostic factors and natural course in a multi-ethnic population. J Gastroenterol Hepatol 23:599–605
66. Kubota J, Ikeda F, Terada R, Kobashi H, Fujioka S, Okamoto R, Baba S et al (2009) Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol 44:1000–1006
67. Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, Cazzagon N et al (2011) A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 31:361–368
68. Baldursdottir TR, Bergmann OM, Jonasson JG, Ludviksson BR, Axelsson TA, Bjornsson ES (2012) The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol 24:824–830